YouTube video by Times Radio

Ardelyx stock news and analysis: IBSRELA and XPHOZAH revenue, commercial execution, market access, cash, secured debt and the key risks for ARDX investors.

YouTube video by BeyoncéVEVO

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Click to view the official SEC document.

Key Points Ardelyx has fully enrolled its Phase 3 ACCEL trial evaluating IBSRELA in adults with chronic idiopathic constipation, or CIC. The study compa

Explore US stock charts with EMA 50 and 200, support, resistance, trendlines and conditional technical scenarios. Daily data from the Merlintrader hub universe.

Ardelyx research on IBSRELA, XPHOZAH, cash and development risks, including September 30 corporate awards. The awards do not change financial guidance.

Ardelyx research on IBSRELA, XPHOZAH, cash and development risks, including September 30 corporate awards. The awards do not change financial guidance.

Investors in Ardelyx, Inc. (NASDAQ: ARDX) can participate in a class action lawsuit for alleged securities law violations affecting share values. Contact DJS Law Group.

Key Points A real-world analysis of 470 adults with irritable bowel syndrome with constipation, or IBS-C, found fewer gastrointestinal-related healthcare v

Ardelyx research on IBSRELA, XPHOZAH, cash and development risks, including September 30 corporate awards. The awards do not change financial guidance.

Adder’s next-generation KVM over IP technology supports distributed computers in applications including video walls, medical imaging, and remote access for the industrial sector. The ARDx platform is a ground-up design comprising an embedded KVM server designed for flexible deployment. Delivering out-of-band remote access and management, users experience low-latency video, audio, and USB connectivity. With the […]

SAN DIEGO, Sept. 21, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Ardelyx, Inc. (NASDAQ: ARDX) common stock between January 13, 2025 and August 6, 2026, inclusive (the "Class Period"). Ardelyx, Inc. develops and commercializes medicines, including ISBRELA for the treatment of irritable bowel syndrome with constipation and XPHOZAH for reducing serum phosphorus in adults with chronic kidney disease on dialysis. The complaint alleges that Ardelyx, Inc. misled investors regarding the true state of Ardelyx's commercial performance and growth prospects for its two core drug products. Investors who suffered significant losses during the Class Period may be eligible to participate in the lawsuit and should contact Robbins LLP before the November 16. 2026, lead plaintiff deadline. Why Was Ardelyx Sued? According to the complaint, during the Class Period, defendants provided investors with material information concerning Ardelyx's fiscal year 2026 revenue outlook for its two core drug products, XPHOZAH and IBSRELA, as well as their anticipated long-term growth. Defendants' statements included, among other things, confidence in the Company's continued commercial growth and ability to execute its commercial strategy to overcome payer...

Ardelyx $ARDX: Q2 growth, revised IBSRELA guidance, September conferences, XPHOZAH access, debt and ACCEL clinical milestones.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.